儿童和青少年心力衰竭:关于诊断方法和管理的最新情况
Amit Agrawal1, Dalwinder Janjua2, Abdulrahman Ahmed Alsayed Ali Zeyada3
1Department of Pediatrics, Gandhi Medical College, Bhopal, MP, India.
Clinical and experimental pediatrics
|June 23, 2023
概括
与成人相比,儿科心力衰竭 (PHF) 需要不同的诊断和治疗策略. 评估相互关联的因素并考虑PHF病理生理学对于有效的管理和改善结果至关重要.
科学领域:
- 儿童心脏病学 儿童心脏病学
- 心血管医学 心血管医学
- 临床儿科 临床儿科
背景情况:
- 儿科心力衰竭 (PHF) 是一种复杂的综合征,其结果是儿童的心脏功能障碍或结构性心脏病.
- 与成人心力衰竭相比,PHF需要不同的诊断和治疗方法.
- 了解PHF独特的病理生理学对于有效的临床管理至关重要.
研究的目的:
- 审查有关儿科心力衰竭 (PHF) 管理的当前文献.
- 为了突出PHF诊断和治疗的最新进展.
- 强调儿童患者需要量身定制的治疗策略.
主要方法:
- 在MEDLINE/PubMed,Google Scholar和临床试验注册表中进行了全面的文献搜索.
- 关键词包括"儿科心力衰竭"",儿童心力衰竭"",管理"和"消血疗法".
- 审查重点关注PHF的诊断进展和治疗考虑.
主要成果:
- 最近的诊断工具,如心脏MRI和高级心声回声学,改善了PHF的理解.
- 评估必须包括心肌功能,血液动力学,节律,门功能和营养状况.
- 由于异质的机制和可变的药理动力学,成人心力衰竭药物在儿童中的有效性是不确定的.
结论:
- 临床医生在选择治疗时必须考虑相互关联的因素和PHF特异性病理生理学.
- 进一步的临床试验对于确定药物在儿科患者群体中的疗效和安全至关重要.
- 多学科的方法对于改善儿科心力衰竭的结果至关重要.
相关概念视频
01:30Heart Failure V: Medical Management
15
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
15
01:22Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
01:30Heart Failure IV: Classification and Diagnostic Evaluation
20
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
20
01:30Heart Failure VII: Nursing Interventions
111
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
111
01:29Cardiomyopathy V: Interprofessional Care
18
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
18
01:30Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11